Literature DB >> 9488691

Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1.

Y Feng1, D Chung, L Garrard, G McEnroe, D Lim, J Scardina, K McFadden, A Guzzetta, A Lam, J Abraham, D Liu, G Endemann.   

Abstract

Peptides or small molecules that can block the interaction of the integrin Mac-1 with its receptor, intercellular adhesion molecule-1 (ICAM-1), have not previously been developed. We studied this interaction by measuring the adherence of ICAM-1-expressing Chinese hamster ovary (CHO) cells to immobilized, purified Mac-1. Nucleotide sequence information was obtained for the complementarity determining regions (CDRs) of three antibodies (44aacb, MY904, and 118.1) shown to block Mac-1-mediated cell adherence. Peptides were synthesized based on the predicted amino acid sequences of the CDRs and tested for the ability to block cell adhesion to Mac-1. Peptides derived from CDR1 of 44aacb, CDR2 of 118.1, and CDRs 1 and 3 of MY904 heavy chains were found to possess blocking activity at 10-100 muM. This may indicate that one or two CDRs contribute disproportionately to the antibody binding affinity. The binding of ligands to Mac-1 has been shown to require a region of the alpha-chain known as the I- or A-domain. We have recombinantly produced Mac-1 I-domain, and show that it is also capable of supporting the adherence of ICAM-1-expressing CHO cells. The adherence of ICAM-1-CHO cells to the I-domain is inhibited by 44aacb and 118.1 and by the CDR peptides from 44aacb and 118.1. By using phage display of peptide libraries based on the 118.1 CDR peptide with five residues randomized, we were able to identify a novel peptide inhibitor of Mac-1 with substitutions at all five positions. These peptides provide lead structures for development of Mac-1 antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488691     DOI: 10.1074/jbc.273.10.5625

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18.

Authors:  Jun Y Park; M Amin Arnaout; Vineet Gupta
Journal:  J Biomol Screen       Date:  2007-04

2.  Molecular Targeting of Immunosuppressants Using a Bifunctional Elastin-Like Polypeptide.

Authors:  Yaping Ju; Hao Guo; Frances Yarber; Maria C Edman; Santosh Peddi; Srikanth Reddy Janga; J Andrew MacKay; Sarah F Hamm-Alvarez
Journal:  Bioconjug Chem       Date:  2019-08-23       Impact factor: 4.774

3.  High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding.

Authors:  Mohd Hafeez Faridi; Dony Maiguel; Brock T Brown; Eigo Suyama; Constantinos J Barth; Michael Hedrick; Stefan Vasile; Eduard Sergienko; Stephan Schürer; Vineet Gupta
Journal:  Biochem Biophys Res Commun       Date:  2010-02-25       Impact factor: 3.575

4.  Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides.

Authors:  E Koivunen; T M Ranta; A Annila; S Taube; A Uppala; M Jokinen; G van Willigen; E Ihanus; C G Gahmberg
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

Review 5.  The structural basis of antibody-antigen recognition.

Authors:  Inbal Sela-Culang; Vered Kunik; Yanay Ofran
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

Review 6.  Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Authors:  Alan Berezov; Mark I Greene; Ramachandran Murali
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

7.  Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.

Authors:  Luciano Polonelli; José Pontón; Natalia Elguezabal; María Dolores Moragues; Claudio Casoli; Elisabetta Pilotti; Paola Ronzi; Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Domenico Leonardo Maffei; Walter Magliani; Stefania Conti; Luiz R Travassos
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.